BIOABioAge Labs, Inc.
Pharmaceutical Preparations
- Revenue
- $9M
- Operating margin
- -1031.5%
- EBITDA
- −$93M
- 19% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$67M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired130% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|
| Revenue | — | $0 | $9M | |
| Operating income | −$48M | −$78M | −$93M | 19% |
| Net income | −$64M | −$71M | −$81M | 13% |
| Operating cash flow | −$37M | −$52M | −$82M | 58% |
| Capex | $166K | $366K | $719K | 96% |
| Stock-based comp | $3M | $7M | $12M | 68% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.